<< Under-five mortality rate continues to decline | Obama: 'Time for bickering is over' on health care reform >>

Read in | English | Español | العربية | Ελληνικά | Русский

New Drug Application for trabectedin approved by the FDA

Published on September 11, 2009 at 12:46 AM · No Comments

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer. The agency has requested additional information, including overall survival data from the company's ongoing pivotal trial and additional clinical pharmacology studies.

Centocor Ortho Biotech Products continues to believe that trabectedin has an important role in the treatment of patients with ovarian cancer. The company is reviewing the FDA's letter and will respond to the agency's questions as quickly as possible.

The NDA for trabectedin was submitted to the FDA in November 2008.

http://www.centocor.com/

8716f310-5b22-42ee-8728-99945d3f83e7|0|.0

Posted in: Pharmaceutical News

Tags: Cancer, Cell, DNA, Doxorubicin, Education, Immunology, Liposome, Nephrology, New Drug Application, Oncology, Ovarian Cancer, Pharmacology

Related posts

First patient treated with MagForce's NanoTherm therapy for recurrent glioblastomaNanostart-holding MagForce AG, a leading medical technology company focusing on nanomedicine in onco...
WHO concerned about radiation levels in food near damaged Japanese nuclear plantA WHO spokesperson "said on Monday that the detection of radiation in food after an earthquake damag...
Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%Abbott today announced financial results for the first quarter ended March 31, 2010.
Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusionsT cell receptors are among the most important molecules in the immune system because of their role i...
VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conferenceVIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious huma...
Opinions: Doctors in developing nations; foreign aidIn a New York Times opinion piece that focuses on health reform in the U.S., Shannon Brownlee, a sen...
ALF, Celsion partner to educate physicians about primary liver cancer treatmentsCelsion Corporation (NASDAQ:CLSN) and the American Liver Foundation (ALF) announced today that they ...
New technique to determine tumor methylation statusCurrent research suggests that a new technique to determine tumor methylation status can be used in ...
Stents no help for patients with narrow kidney arteriesUsing stents to open up kidney arteries is commonly done in patients with atherosclerotic renovascul...
Scientists reveal a new target to fight bad cholesterolScientists have uncovered a new region in the genome that is responsible for the body's ability to r...
Molecular evolution of limb lengthIn the January 15th issue of G&D, a research team led by Dr. Richard Behringer at MD Anderson Cancer...
FDA approves VELCADE plus DOXIL combination for multiple myelomaOrtho Biotech Products has announced the U.S. Food and Drug Administration (FDA) has approved the us...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.